Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).

被引：4
|
作者：
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ S Florida, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] West Virginia Univ, Morgantown, WV USA
[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14019
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [2] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Houot, Roch
    Minnema, Monique
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
  • [3] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
    Topp, Max S.
    van Meerten, Tom
    Wermke, Martin
    Lugtenburg, Elly J.
    Minnema, Monique C.
    Song, Kevin W.
    Thieblemont, Catherine
    Jiang, Yizhou
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Hout, Roch
    Minnema, Monique C.
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin W.
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rong
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
  • [5] Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
    Locke, Frederick L.
    Siddiqi, Tanya
    Jacobson, Caron Alyce
    Ghobadi, Armin
    Ahmed, Sairah
    Miklos, David Bernard
    Perales, Miguel-Angel
    Munoz, Javier
    Logan, Brent
    Hu, Zhen-Huan
    Miao, Harry H.
    Singh, Kanwarjit
    Shah, Jina
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).
    Jacobson, Caron A.
    Locke, Frederick Lundry
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobadi, Armin
    Miklos, David Bernard
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew Alexander
    Herr, Megan
    Hill, Brian T.
    Ganguly, Siddhartha
    Dong, Hua
    Nikiforow, Sarah
    Xie, Jing
    Xu, Hairong
    Hooper, Michele
    Kawashima, Jun
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Jacobson, C. A.
    Oluwole, O. O.
    Munoz, J.
    Lekakis, L. J.
    Topp, M. S.
    Avivi, I
    Kim, J. J.
    Chu, R.
    Zheng, L.
    Rossi, J. M.
    Bot, A.
    Neelapu, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
  • [8] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
    Diakite, I
    Lin, V. W.
    Klijn, S.
    Navale, L.
    Purdum, A. G.
    Fenwick, E.
    Botteman, M.
    van Hout, B.
    VALUE IN HEALTH, 2019, 22 : S41 - S41
  • [9] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
    Hathway, Joanne
    Purdum, Anna
    Lin, Vincent W.
    Cyr, Philip
    Westin, Jason
    Jensen, Ivar
    BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
  • [10] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick
    Bartlett, Nancy
    Jacobson, Caron
    Oluwole, Olalekan
    Munoz, Javier
    Lekakis, Lazaros
    Topp, Max
    Avivi, Irit
    Kim, Jenny
    Chu, Rong
    Zheng, Lianqing
    Rossi, John
    Bot, Adrian
    Neelapu, Sattva
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
12345